# US 2022/0033808 A1 · Methods and compositions for nucleic acid-guided nuclease cell targeting screen

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033808 A1
- Document ID: US20220033808A1
- Status: Published application
- Kind: A1
- Application number: 17/507,324
- Filed: 2021-10-21
- Published: 2022-02-03
- Earliest claimed: 2019-04-24
- Assignees: Spotlight Therapeutics
- Applicants: Spotlight Therapeutics
- Inventors: Akshay Tambe; Hariharan Jayaram; Steven Strutt
- Web page: https://patentgrep.com/patent/US20220033808A1

## CPC

- C12N 15/1065: {Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/1034: {Isolating an individual clone by screening libraries}
- C12N 15/1082: {Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/8213: {Targeted insertion of genes into the plant genome by homologous recombination}
- C12N 15/87: Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N 15/905: {in yeast}
- C40B 40/02: Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
- C07K 2319/00: Fusion polypeptide
- C07K 2319/09: containing a nuclear localisation signal
- C07K 2319/10: containing a tag for extracellular membrane crossing, e.g. TAT or VP22
- C07K 2319/21: containing a His-tag
- C07K 2319/43: containing a FLAG-tag
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Methods and compositions related to a nucleic acid-guided nuclease cell targeting screen are provided. The invention relates to compositions and methods for identifying cell targeting proteins that, when associated with a nucleic acid-guided nuclease (such as Cas9), enables at least the nucleic acid-guided nuclease to be targeted to the surface of a target cell or internalized by a target cell, i.e., a cell targeted by the cell targeting agent.

## Claims

### Claim 1

A method of identifying a cell targeting agent, the method comprising:
providing a plurality of ribonucleoproteins (RNPs) each comprising an RNA-guided nuclease fusion protein and a unique identifying RNA (uiRNA), wherein the RNA-guided nuclease fusion protein comprises an RNA-guided nuclease, or a functional fragment thereof, and a test protein; and wherein the uiRNA comprises a guide RNA (gRNA) and a sequence identifier;
contacting the RNPs with a population of target cells;
isolating RNA from the population of target cells, thereby obtaining isolated RNA; and
testing the isolated RNA for the presence of the identifier sequence, wherein the presence of the identifier sequence indicates that the test protein is a cell targeting agent.

### Claim 2

A method of identifying a cell targeting agent, the method comprising:
providing a vector encoding an RNA-guided nuclease fusion protein comprising an RNA-guided nuclease, or a functional fragment thereof, and a test protein, and encoding a unique identifying RNA (uiRNA) comprising a guide RNA (gRNA) and a sequence identifier;
transferring the vector to a host cell suitable to express the RNA-guided nuclease fusion protein and the uiRNA;
expressing the RNA-guided nuclease fusion protein and the uiRNA in the host cell, such that ribonucleoproteins (RNPs) each comprising the RNA-guided nuclease fusion protein and the uiRNA are formed;
isolating the RNPs from the host cell;
contacting the RNPs with a population of target cells;
isolating RNA from the population of target cells; and
testing the isolated RNA for the presence of the identifier sequence, wherein the presence of the identifier sequence indicates that the test protein is a cell targeting agent.

### Claim 3 (depends on 2)

The method of claim 2, wherein portions of the vector encoding the nucleic acid sequence identifier and the test protein are sequenced prior to the vector being transferred into the host cell, thereby providing a reference for identifying the test protein.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the presence of the identifier sequence is detected using polymerase chain reaction (PCR) or a nucleic acid microarray.

### Claim 5 (depends on 2, 3, 4)

The method of any one of claims 2-4, wherein the vector is in a plurality of vectors and the plurality of vectors are transferred into host cells under conditions such that the average vector per host cell is 1 or more.

### Claim 6 (depends on 2, 3, 4, 5)

The method of any one of claims 2-5, wherein the vector comprises a first promoter operatively linked to a nucleic acid sequence encoding the RNA-guided nuclease fusion protein, and comprises a second promoter operatively linked to a nucleic acid sequence encoding the uiRNA.

### Claim 7 (depends on 6)

The method of claim 6, wherein the first and second promoter are each inducible such that the expression level of the RNA-guided nuclease fusion protein and the expression level of the uiRNA can be controlled to obtain RNPs.

### Claim 8 (depends on 6)

The method of claim 6, wherein the first and/or second promoter is a constitutive promoter.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, wherein the vector comprises a selectable marker to select for the host cell into which the vector has been transferred.

### Claim 10 (depends on 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 2-9, wherein the vector comprises a bacterial origin of replication.

### Claim 11 (depends on 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 2-9, wherein the vector comprises a eukaryotic origin of replication.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1-11, wherein the cell targeting agent either internalizes into a compartment of the target cell or binds to the cell surface of the target cell.

### Claim 13 (depends on 12)

The method of claim 12, wherein the compartment is a membrane-bound organelle or cytoplasm.

### Claim 14 (depends on 13)

The method of claim 13, wherein the membrane-bound organelle is a nucleus, endoplasmic reticulum, Golgi apparatus, vacuole, lysosome, endosome, or mitochondria.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of any one of claims 1-14, wherein the isolated RNA is obtained from membrane-bound organelles that are extracted from the target cell prior to RNA isolation.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1-13, wherein the isolated RNA is obtained from cytoplasm that is extracted from the target cell prior to RNA isolation.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any one of claims 1-16, wherein the testing step comprises reverse-transcribing the isolated RNA to producing cDNA, and sequencing the cDNA to determine the presence of the identifier sequence.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any one of claims 1-16, wherein the testing step comprises sequencing the isolated RNA to determine the presence of the identifier sequence.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, wherein the test protein is a peptide.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, wherein the test protein is an antigen-binding protein.

### Claim 21 (depends on 20)

The method of claim 20, wherein the antigen binding protein is a nanobody, a domain antibody, an scFv, a Fab, a diabody, a BiTE, a diabody, a DART, a minibody, a F(ab′)2, an intrabody, or an antibody mimetic.

### Claim 22 (depends on 21)

The method of claim 21, wherein the antibody mimetic is an adnectin (i.e., fibronectin based binding molecules), an affilin, an affimer, an affitin, an alphabody, an affibody, a DARPin, an anticalin, an avimer, a fynomer, a Kunitz domain peptide, a monobody, a nanoCLAMP, a unibody, or a versabody, an aptamer, or a cyclotide.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method of any one of claims 1-17, wherein the test protein is a ligand, or portion thereof.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 1-23, wherein the host cell is a eukaryotic cell.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 1-23, wherein the host cell is a bacterial cell.

### Claim 26 (depends on 25)

The method of claim 25, wherein the bacterial cell is E. coli.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 1-26, wherein the RNA-guided nuclease is a Class 2 Cas polypeptide.

### Claim 28 (depends on 27)

The method of claim 27, wherein the Class 2 Cas polypeptide is a Type II, Type V, or Type VI Cas polypeptide.

### Claim 29 (depends on 28)

The method of claim 28, wherein the Type II Cas polypeptide is Cas9.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 1-29, wherein the target cells are mammalian cells.

### Claim 31 (depends on 30)

The method of claim 30, wherein the mammalian cells are hematopoietic stem cells (HSC), neutrophils, T cells, B cells, dendritic cells, macrophages, ocular cells, or fibroblasts.

### Claim 32

A cell expression vector comprising:
a nucleic acid encoding an RNA-guided nuclease operably linked to a cloning site for inserting a nucleic acid of a test protein, thereby forming an RNA-guided nuclease fusion protein comprising the RNA-guided nuclease and the test protein; and
a nucleic acid encoding a unique identifying RNA (uiRNA), wherein the uiRNA comprises a guide RNA and a sequence identifier.

### Claim 33 (depends on 32)

The cell expression vector of claim 32, further comprising the nucleic acid encoding the test protein.

### Claim 34 (depends on 32, 33)

The cell expression vector of claim 32 or 33, wherein the expression vector is a plasmid.

### Claim 35 (depends on 32, 33, 34)

The cell expression vector of any one of claims 32-34, wherein the cell expression vector comprises a first promoter operatively linked to the nucleic acid sequence encoding the RNA-guided nuclease, and comprises a second promoter operatively linked to the nucleic acid sequence encoding the uiRNA.

### Claim 36 (depends on 35)

The cell expression vector of claim 35, wherein the first and second promoter each comprise an inducible element such that the expression level of the RNA-guided nuclease fusion protein and the expression level of the uiRNA can be controlled.

### Claim 37 (depends on 35, 36)

The cell expression vector of claim 35 or 36, wherein the first and/or second promoter is T7 or T5.

### Claim 38 (depends on 35)

The cell expression vector of claim 35, wherein the first and/or second promoter is a constitutive promoter.

### Claim 39 (depends on 32, 33, 34, 35, 36, 37, 38)

The cell expression vector of any one of claims 32-38, wherein the vector comprises a selectable marker.

### Claim 40 (depends on 32, 33, 34, 35, 36, 37, 38, 39)

The cell expression vector of any one of claims 32-39, wherein the vector comprises a bacterial origin of replication.

### Claim 41 (depends on 32, 33, 34, 35, 36, 37, 38, 39)

The cell expression vector of any one of claims 32-39, wherein the vector comprises a eukaryotic origin of replication.

### Claim 42 (depends on 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The cell expression vector of any one of claims 32-41, wherein the RNA-guided nuclease is a Class 2 Cas polypeptide.

### Claim 43 (depends on 42)

The cell expression vector of claim 42, wherein the Class 2 Cas polypeptide is a Type II, Type V, or Type VI Cas polypeptide.

### Claim 44 (depends on 43)

The cell expression vector of claim 43, wherein the Type II Cas polypeptide is Cas9.

### Claim 45 (depends on 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A kit comprising the cell expression vector of any one of claims 32-44.

### Claim 46 (depends on 45)

The kit of claim 45, wherein the kit further comprises reagents for inserting the polynucleotide encoding the test protein into the cloning site of the cell expression vector.

### Claim 47 (depends on 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

An isolated cell comprising the cell expression vector of any one of claims 32-44.

### Claim 48 (depends on 47)

The cell of claim 47, wherein the cell is a eukaryotic cell or a bacterial cell.

### Claim 49 (depends on 48)

The cell of claim 48, wherein the eukaryotic cell is a mammalian cell, a yeast cell, or an insect cell.

### Claim 50 (depends on 49)

The cell of claim 49, wherein the mammalian cell is a COP cell, an L cell, a C127 cell, an Sp2/0 cell, an NS-0 cell, an NIH3T3 cell, a PC12 cell, a PC12h cell, a BHK cell, a CHO cell, a COS1 cell, a COS3 cell, a COST cell, a CV1 cell, a Vero cell, a HeLa cell, an HEK-293 cell, a PER C6 cell, a cell derived from diploid fibroblasts, a myeloma cell, or HepG2.

### Claim 51 (depends on 49)

The cell of claim 49, wherein the yeast cell is Pichia pastoris or Saccharomyces cerevisiae and the insect cell is Spodoptera frugiperda.

### Claim 52 (depends on 48)

The cell of claim 48, wherein the bacterial cell is an E. coli cell.

### Claim 53 (depends on 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A method for producing at least one RNP comprising the RNA-guided nuclease fusion protein and the uiRNA comprising culturing a cell comprising the expression vector of any one of claims 32-44 in a cell culture medium under conditions allowing expression and assembly of the at least one RNP.

### Claim 54 (depends on 51)

The method of claim 51, wherein the at least one RNP is/are secreted into the cell culture medium and the method further comprises the step of isolating from the cell culture medium the at least one RNP.

### Claim 55 (depends on 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A library of cell expression vectors comprising a plurality of the cell expression vector of any one of claims 32-44.

### Claim 56 (depends on 55)

The library of claim 55, wherein each of the cell expression vectors comprises a different sequence identifier.
